Mitsubishi Tanabe Pharma competitive analysis

Explore patent oppositions filed by Mitsubishi Tanabe Pharma against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
Monoclonal Antibodies Against The Rgm A Protein For Use In The Treatment Of Retinal Nerve Fiber Layer DegenerationABBOTTSep 1, 2016

Explore Mitsubishi Tanabe Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
Jun 19, 2024Edaravone Suspension For Oral Administration1
Oct 7, 2020Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter2
Oct 23, 2019Combination Therapy Comprising Sglt Inhibitors And Dpp4 Inhibitors1
Apr 3, 2019Medicinal Agent For Treating Amyotrophic Lateral Sclerosis Or Preventing Progression Of Phase Of Amyotrophic Lateral Sclerosis2
Mar 28, 2018Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) Or Disease Attributable To Als2
Sep 9, 2015T Cell Activation Inhibitor, Pharmaceutical Composition Containing Same, And Screening Method For T Cell Activation Inhibiting Substance1

Latest PTAB cases involving Mitsubishi Tanabe Pharma

Discover the latest PTAB cases involving Mitsubishi Tanabe Pharma, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Mitsubishi Tanabe Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
MITSUBISHI TANABE PHARMA19 - -
ABBVIE DEUTSCHLAND - 2 - -
MAIWALD PATENTANWALTS168 - - -
MAIWALD PATENT- UND RECHTSANWALTSGESELLSCHAFT MBH54 - - -